

Quarterly Report & Appendix 4C: Q1 FY2027

Highlights:

Clinical and regulatory development activity

- Completed enrolment of all 250 participants in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial across 78 activated US clinical sites, bringing forward the anticipated topline readout to late Q4 FY2027 (late Q2 CY2027)
- Expanded Access Program (EAP) for NUZ-001 fully funded through a multi-year US National Institutes of Health grant, providing access for up to 200 people living with ALS in the US for up to 96 weeks
- Subsequent to quarter end, FDA Type C meeting feedback noted the HEALEY trial may serve as the single registrational study to support a traditional approval pathway for NUZ-001, subject to meeting the requirement for substantial evidence of effectiveness
- EMA Scientific Advice received, outlining the requirements for a potential EU marketing authorisation for NUZ-001, consistent with the Company's expectations

Leadership and strategic partnerships

- Dr Chris Bremer appointed CEO, bringing 20+ years of international pharmaceutical leadership and over US\$1Bn in executed licensing transactions
- Mr Sergio Duchini transitioned from Interim Executive Chairman, back to Non-Executive Chairman following Dr Bremer's commencement on 1 October 2026
- Strengthened strategic relationship with Elanco Animal Health through the appointment of Dr Steve Nanchen as Elanco's representative Board Observer

Capital management and funding activity

- Executed strategic R&D financing facility of up to A\$17.5m with Dare Capital, with an initial non-dilutive drawdown of approximately A\$8.3m completed in August 2026
- Redeemed 1,000,000 Obsidian convertible notes, with 750,000 notes remaining on issue at the completion of the transaction
- Neurizon remains fully funded through the HEALEY topline readout and completion of the study
- \$11.4m cash at 30 September 2026; operating outflows \$7.9m for the quarter

Post Quarter End

- Hosted Neurizon Leadership Roundtable on 8 October 2026, introducing the Company's new CEO and outlining clinical, regulatory and corporate priorities ahead of the anticipated HEALEY ALS Platform Trial topline readout.

28 October 2026 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ, OTCQB: NUZTF) ("Neurizon" or "the Company"), a late clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to provide its Quarterly Activities Report and Appendix 4C for the period ended 30 September 2026 (Q1 FY2027).

The September quarter marked an important transition for Neurizon as the Company completed enrolment in its lead clinical development program and advanced its regulatory, operational and financial preparations ahead of the anticipated HEALEY ALS Platform Trial topline results in late Q2 CY2027.

With all 250 participants enrolled in Regimen I, Neurizon's focus has shifted towards continued clinical execution and readiness for the next stages of development. The quarter also saw the award of NIH-funding for an Expanded Access Program for NUZ-001, the appointment of Dr Chris Bremer as Chief Executive Officer and further capital management initiatives aimed at supporting the Company's development priorities.

Subsequent to quarter end, written feedback from the US FDA provided additional clarity to inform Neurizon's regulatory planning, including its strategy to evaluate Regimen I as a potential registrational study for NUZ-001.

Chief Executive Officer, Dr Chris Bremer said: "I am delighted to have joined Neurizon at such an important stage of its development, with the Company entering a period of significant clinical and regulatory activity.

The September quarter delivered the milestones that define the path to our pivotal readout. Completing enrolment in Regimen I of the HEALEY ALS Platform Trial represents a major achievement for the program. With 250 participants now enrolled, our focus is on disciplined trial execution and preparing the organisation for the anticipated topline readout in late Q4 FY2027 (late Q2 CY2027).

The NIH's decision to fund an Expanded Access Program represents an important development for NUZ-001 program and our partnership with the Healey & AMG Center. It is expected to broaden access to NUZ-001 for eligible people living with ALS who cannot participate in clinical trials, while providing opportunities to collect additional long-term safety and clinical data.

Alongside these developments, we have also strengthened our balance sheet through non-dilutive R&D funding and the partial redemption of the Obsidian convertible notes. My immediate priority is disciplined execution as Regimen I progresses towards topline results, while ensuring Neurizon is ready for the regulatory, partnering and commercial pathways that may follow."

Clinical progress:

The Company achieved a number of significant clinical milestones in the history of the NUZ-001 program during the quarter. Neurizon announced that the final participant had completed baseline assessments and commenced treatment, with 250 participants enrolled across 78 activated clinical trial sites throughout the US.

Enrolment was completed in under five months from first participant dosing, the fastest site activation and enrolment of any regimen in HEALEY history, following expansion of the participant cohort from 160 participants. The expanded study maintains its original statistical power, with no change to Neurizon's funding requirement through to topline readout, which will now occur in late Q2 CY2027.

Regimen I is a double-blind, placebo-controlled study in which participants are randomised 3:1 to NUZ-001 or placebo. Participants are now progressing through the planned 36-week randomised controlled treatment phase, followed by a 36-week Active Treatment Extension. The primary endpoint is the change in ALSFRS-R and survival from baseline to Week 36.

Regulatory progress:

Subsequent to the end of the period, Neurizon received written feedback from the FDA in response to its Type C meeting request for NUZ-001. The FDA noted that positive results from the Phase 2/3 HEALEY ALS Platform Trial could support a traditional approval pathway and the trial may serve as the single registrational study for an NDA for NUZ-001, subject to the results and supporting evidence meeting the requirements for substantial evidence of effectiveness.

The FDA also agreed with Neurizon's approach to the measurement of plasma neurofilament light chain (NfL), a biomarker of neurodegeneration, and outlined the types of evidence that would be required for NfL to support an accelerated approval. The FDA further advised that Neurizon may resubmit a request for Fast Track Designation based on available data, and the Company is evaluating the timing of any resubmission.

Neurizon has also advanced its regulatory program, receiving Scientific Advice from the European Medicines Agency (EMA) regarding the development pathway for NUZ-001 in ALS. The advice provides clarity on the requirements for potential marketing authorisation in the European Union (EU). The EMA advised that an additional Phase 3 study of at least 18 months' duration, incorporating participants from multiple European centres, would ordinarily be required to support a European marketing authorisation application for ALS. The EMA also noted that reliance on a single pivotal study could be considered where the results provide "particularly compelling" evidence, supported by additional confirmatory evidence.

Accordingly, results from the ongoing HEALEY ALS Platform Trial (Regimen I) may provide an opportunity for Neurizon to further engage with the EMA regarding the clinical evidence required to support a potential European marketing authorisation application.

The US remains Neurizon's immediate commercial priority, with the Company focused on successfully completing HEALEY Regimen I and progressing NUZ-001 towards FDA approval. The EMA feedback provides important guidance for the Company's European development strategy, which will be further assessed following the availability of HEALEY topline results.

HEALEY Regimen I remains fully enrolled and on track, with topline results expected in late Q2 CY2027.

Expanded Access Program:

Neurizon announced that the NIH had awarded a multi-year grant (Project Number 1U01NS153995-01) to fund an Expanded Access Program for NUZ-001 in ALS. The EAP will provide access to NUZ-001 for up to 200 people living with ALS in the US who are otherwise ineligible for clinical trials, for a treatment period of up to 96 weeks. Continuation of the EAP beyond the HEALEY topline results is contingent on a positive trial outcome.

The Sean M. Healey & AMG Center for ALS at Mass General Brigham is the prime grant recipient and will lead clinical and operational execution across approximately 20 ALS clinical sites, including sites participating in the HEALEY ALS Platform Trial, together with a national virtual site designed to extend access to people living in rural and underserved areas across all 50 US states. Neurizon is a subawardee and is the regulatory sponsor and IND holder, with its supply of NUZ-001 supported through its long-term supply agreement with Elanco Animal Health.

Importantly, the EAP is fully funded through the NIH award, which provides for EAP-related drug supply, manufacturing, and specified regulatory, safety monitoring and operational costs associated with Neurizon's participation. The EAP is therefore non-dilutive to shareholders, while expanding the long-term safety database for NUZ-001 and collecting survival, biomarker and real-world data from a broader ALS population. Start-up activities are underway, with participant enrolment targeted to commence in Q3 FY2027 (Q1 CY2027). The EAP operates alongside, and does not affect the conduct, randomisation or blinding of the Regimen I in the HEALEY ALS Platform trial.

Commercial supply readiness and strategic partnerships:

Neurizon's strategic relationship with Elanco Animal Health continued to strengthen during the quarter. The Company announced the appointment of Dr Steve Nanchen, Senior Advisor, External Innovation at Elanco, as Elanco's representative Board Observer. Dr Nanchen brings nearly 20 years of experience across animal health and pharmaceuticals, including leadership of global research programs and licensing transactions at Elanco and Novartis Animal Health, and is one of the inventors of lotilaner (Credelio®).

His appointment succeeds Ms Justine Conway and further strengthens Neurizon's strategic relationship with Elanco Animal Health, which supplies the active pharmaceutical ingredient used in NUZ-001 under a long-term supply agreement.

The supply arrangement supports Neurizon's ongoing clinical development activities, including the NIH-funded Expanded Access Program, and forms an important component of the Company's preparations for potential future regulatory and commercial requirements.

Community, shareholder and industry engagement initiatives:

During the quarter, Neurizon continued to strengthen its engagement with the global ALS research, clinical and patient advocacy communities through participation in scientific and industry conferences, including ALS Nexus, and several community webinars hosted by the Sean M. Healey & AMG Center for ALS. These activities provided opportunities to share updates on the NUZ-001 clinical development program, engage with researchers, clinicians and people living with ALS, and contribute to broader discussions on emerging ALS research.

The Company continued to actively engage with shareholders, institutional investors and the broader ALS community throughout the quarter. On 29 July 2026, Neurizon hosted an in-person investor briefing in Melbourne,

where Interim Executive Chairman Mr Sergio Duchini provided an update on the Company's progress and upcoming milestones, followed by a Q&A session with the leadership team.

The Company also continued to pursue industry engagement and potential strategic collaboration opportunities through participation in relevant biotechnology and partnering forums.

Neurizon also released its 2026 Annual Report on 25 August 2026, published video updates to shareholders covering the Company's Q4 FY2026 milestones and financial position, and participated in a Sharewise investor webinar in September 2026.

Subsequent to the end of the reporting period, Neurizon released an updated investor presentation and hosted a Leadership Roundtable webinar on 8 October 2026, featuring recently appointed CEO Dr Chris Bremer, Non-Executive Chairman Mr Sergio Duchini and Chief Financial Officer Mr Dan O'Connell, followed by a live Q&A.

These activities supported the Company's ongoing engagement with scientific, clinical, investor and patient stakeholders, while increasing awareness of NUZ-001 and Neurizon's upcoming value-defining clinical, regulatory and corporate milestones among Australian and international investors and potential strategic partners.

Corporate and funding developments:

During the period, Neurizon announced the appointment of Dr Chris Bremer as CEO, following an extensive international executive search. Dr Bremer brings over 20 years of international pharmaceutical and biotechnology leadership experience, including approximately 20 years at Grünenthal, where his roles included Executive Vice President, Early Products & Commercial Opportunities and Interim Chief Commercial Officer. He has executed more than US\$1Bn in licensing transactions and previously served as Chief Development Officer of Navigo Proteins and founding CEO of GAIASO Theranostics. Dr Bremer commenced as CEO on 1 October 2026, at which time Mr Sergio Duchini transitioned from Interim Executive Chairman to Non-Executive Chairman.

Neurizon continued to execute its capital management strategy during the quarter. The Company established a strategic R&D financing facility of up to A\$17.5m with the Dare Capital Loan Fund, secured solely against the Company's R&D Tax Incentive refund, with annual extension options covering the FY2027 and FY2028 claims. Neurizon also completed an initial drawdown of ~A\$8.3m in relation to its FY2026 R&D Tax Incentive refund. The facility provides non-dilutive capital earned through the Company's investment in eligible R&D activities, including the HEALEY ALS Platform Trial, and reduces reliance on other sources of funding.

Neurizon completed the partial redemption of 1,000,000 convertible notes held by Obsidian for total consideration of US\$1.15m. The redemption completed on 14 September 2026, following which 750,000 convertible notes remain on issue. During the quarter, and prior to the redemption, Obsidian converted 975,500 convertible notes into 28,014,264 ordinary shares.

The Board considers the redemption an appropriate allocation of shareholder funds and consistent with its disciplined approach to capital management and minimising dilution. The Company remains committed to evaluating all available funding alternatives prior to any further drawdown under the convertible note facility, and continues to review its funding structure. Neurizon remains fully funded through the HEALEY topline readout and through to completion of the study.

Near-term outlook and value catalysts:

Near-term Milestones	Timing
Preclinical updates to expand understanding of NUZ-001's mechanism of action	Q2 FY2027
Presentation and participation in scientific and partnering events	Q2/Q3 FY2027
Receipt of R&D Tax Incentive Refund	Q2 FY2027
Expanded Access Program participant enrolment commences	Q3 FY2027
HEALEY Randomised Controlled Trial (RCT) Completion	Early Q4 FY2027
HEALEY Trial database lock	Q4 FY2027
HEALEY Trial topline results	Late Q4 FY2027
Regulatory engagement on data package (FDA, EMA, TGA, PMDA)	Post-topline

Cashflow summary:

During the quarter, Neurizon continued to fund the advancement of its clinical development program for NUZ-001, with particular focus on the HEALEY ALS Platform Trial. Neurizon had net cash outflows from operating activities of \$7.9m during the quarter and held \$11.4m in cash and cash equivalents as at 30 September 2026.

Total operating expenditure for the quarter was higher compared with the prior quarter, predominantly reflecting increased research and development spend, which was focused on the Phase 2/3 HEALEY ALS Platform Trial. Consistent with the Neurizon's deliberate approach to limiting expenditure not directly focused on advancing or de-risking the trial, pre-clinical and other R&D spend was very modest during the quarter.

Labour costs were modestly higher in the current quarter, reflecting the payment of executive incentive payments related to FY2026 and the settlement of payments to the former CEO, including accrued rights on termination of his employment on 14 July 2026. Despite slightly higher one off costs associated with the CEO recruitment and end of financial year compliance expenditure, administrative and corporate costs were materially aligned with the prior quarter, which was 25% lower than the average run rate for the prior three quarters. Maintaining this lower administrative cost level, despite the identified one-off costs, reflects Neurizon's continued focus on disciplined cost management.

Net cash inflows from financing activities of \$6.7m primarily reflected the initial drawdown of approximately \$8.3m under the Dare Capital R&D financing facility, partially offset by the payment of US\$1.15m (~ A\$1.6m) for the redemption of 1,000,000 convertible notes held by Obsidian.

Payments to related parties and their associates during the quarter, which are outlined in Section 6 of the accompanying Appendix 4C to this quarterly activity report, were \$202k. These payments included non-executive director fees and consulting fees as well as salary (including superannuation) for the Interim Executive Chairman.

A copy of the Appendix 4C – Quarterly Cash Flow Report for the quarter is attached.

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For any questions, comments, or further information regarding Neurizon, please email enquiries@neurizon.com, or contact:

Marketing & Corporate Affairs

Lidija Damjanovic

Email: lidija@neurizon.com

Phone: +61 (0) 425 700 504

Investor Relations

Henry Jordan

Email: henry.jordan@sdir.com.au

Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late-clinical stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited.

The Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Neurizon Therapeutics Limited

ABN

35 094 006 023

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(6,009)	(6,009)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(111)	(111)
(d) leased assets	-	-
(e) staff costs	(1,044)	(1,044)
(f) administration and corporate costs	(773)	(773)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	38	38
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (R&D Tax Offset)	-	-
1.9 Net cash from / (used in) operating activities	(7,899)	(7,899)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) term deposits with maturities longer than 3 months at acquisition	-	-
(e) intellectual property	-	-

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) term deposits with maturities longer than 3 months at acquisition	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	8,310	8,310
3.6	Repayment of borrowings	(1,614)	(1,614)
3.7	Transaction costs related to loans and borrowings	(15)	(15)
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	Net cash from / (used in) financing activities	6,681	6,681

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	12,692	12,692
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(7,899)	(7,899)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,681	6,681
4.5	Effect of movement in exchange rates on cash held	(45)	(45)
4.6	Cash and cash equivalents at end of period	11,429	11,429

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	11,429	12,692
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
2	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,429	12,692

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	202
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities *	17,500	8,310
7.2	Credit standby arrangements	-	-
7.3	Other(Convertible notes) **	16,049	1,049
7.4	Total financing facilities	33,549	9,359
7.5	Unused financing facilities available at quarter end		24,190
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. * On 31 July 2026, the Company executed a strategic R&D financing facility for up to \$17.5 million with the Dare Capital Loan Fund secured against the Company's R&D Tax Incentive refund. The facility is a secured loan, with the Dare holding first-ranking security solely over the Company's R&D Tax Incentive refund. An initial drawdown of approximately \$8.3 million was made on 10 August 2026. Interest accrues at 1.25% per month, capitalising monthly, with repayment triggered upon receipt of the R&D Tax Incentive refund from the Australian Taxation Office, with all outstanding amounts to be repaid by 31 December 2026 (subject to market standard extension terms). The Facility carries no establishment fee and includes annual extension options to support the Company's FY2027 and FY2028 R&D Tax Incentive claims. ** On 23 December 2025, Neurizon entered into a convertible note facility agreement with Obsidian Global GP, LLC, a New York-based investment manager, providing for aggregate funding of up to A\$20 million over a two-year term from the date of first purchase. The first tranche of A\$5 million was drawn on 27 February 2026, resulting in the issue of 3,575,500 convertible notes. Of the convertible notes issued, 1,825,000 have been converted into ordinary Shares and 1,000,000 notes were redeemed by the company for US1.15 million on 9 September 2026. As a result 750,000 notes remain outstanding. The convertible note facility has remaining capacity of up to A\$15 million that can be drawn in subsequent tranches, with a minimum of approximately six months required between each drawdown. Converted amounts are not available to be redrawn. The Company has discretion over whether and when to draw further tranches, consistent with its broader capital management strategy of evaluating all available funding options before drawing additional debt.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(7,899)
8.2	Cash and cash equivalents at quarter end (item 4.6)	11,429
8.3	Unused finance facilities available at quarter end (item 7.5)	24,190
8.4	Total available funding (item 8.2 + item 8.3)	35,619
8.5	Estimated quarters of funding available based on cash and cash equivalents under AASB 107 (item 8.4 divided by item 8.1)	4.50
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?
	N/A
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	N/A
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	N/A
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.